DME is the leading cause of blindness in younger and middle-aged adults; Eylea could potentially treat over 6M patients globally.
Regeneron intends to apply for FDA approval of Eylea to treat DME in 2013, a year ahead of plan. Bayer, which sells the drug outside the U.S., will apply for EU authorization.
Eyelea is already used in patients with wet age-related macular edema, the leading cause of blindness among the elderly. (PR)